Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Salmeterol inhaler		Prescribe by brand to ensure patients receive the device they are used to. Check licensed indication (differences among brands). Be aware of differences in excipients among the different brands- APC listing of current formulary brands
Sebelipase alfa (Kanuma®)		For Wolman disease
Selegiline lyophisilate		For patients with swallowing difficulties only
Semaglutide (Wegovy®)	TA875 - Semaglutide for managing overweight and obesity	The use of semaglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. The Wegovy® brand of semaglutide is not commercially available yet.
Sevelamer tablets		Specialist recommendation.
Sildenafil injection		Hospital use only. NHS England commissioned.
Sildenafil tablets		Hospital use only. NHS England commissioned.
Sildenafil tablets		Sildenafil tablets generic
Simvastatin tablets		MHRA advice regarding high dose simvastatin (May 2010): • Simvastatin 80 mg should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks • Prescribers treating patients who are taking simvastatin 80 mg or who are being considered for an up-titration to that dose may need to review their treatment during their next visit, to take into account the new evidence • Patients who are currently taking simvastatin 80 mg should not stop taking their medicine. However, they should be advised to contact their doctor immediately if they experience unexplained muscle pain, tenderness, or weakness • Please report suspected adverse reactions with medicines, including statins, to us via the Yellow Card Scheme (www.yellowcard.gov.uk)
Sirolimus solution	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.